^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L2 inhibitor

    Related drugs:
    over1year
    Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=105, Recruiting, ImmunoGenesis | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    PD-L1 expression
    over2years
    Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3; Trial completion date: Jun 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    almost3years
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Active, not recruiting, Shattuck Labs, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    almost3years
    Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation • MGMT promoter methylation • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
    almost3years
    Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report. (PubMed, Medicine (Baltimore))
    Our case represents a successful attempt at personalized treatment and provides preliminary evidence for the clinical use of downstaging therapy of androgen deprivation therapy, chemotherapy, and add-on zimberelimab for very-high-risk clinically localized PCa.
    Journal • Tumor mutational burden • MSi-H Biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    docetaxel • Yutuo (zimberelimab)
    almost3years
    NCI-2020-02940: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (clinicaltrials.gov)
    P2, N=25, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression • ER expression
    |
    Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)
    almost3years
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Recruiting, Shattuck Labs, Inc. | Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Nov 2022 --> Jul 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    almost3years
    MODULE 2: Current and Future Front-Line Treatment for Metastatic UBC (mUBC) (ASCO-GU 2023)
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. Current clinical role of atezolizumab or pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy Appropriate incorporation of maintenance avelumab after front-line chemotherapy for mUBC Biologic rationale for the investigation of anti-PD-1/PD-L1 antibodies in combination with novel therapies (eg, enfortumab vedotin, erdafitinib) for previously untreated mUBC Recently presented efficacy and safety results from cohort K of the EV-103/KEYNOTE-869 study of first-line pembrolizumab in combination with enfortumab vedotin Potential clinical role of up-front pembrolizumab/enfortumab vedotin for patients with mUBC who are ineligible to receive cisplatin-based chemotherapy Preliminary data with erdafitinib in combination with cetrelimab for patients with previously untreated mUBC with FGFR3 or FGFR2 genetic alterations
    PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • Bavencio (avelumab) • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv) • cetrelimab (JNJ-63723283)
    almost3years
    Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=35, Recruiting, Peter Hosein, MD | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR
    |
    Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)
    almost3years
    Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) (clinicaltrials.gov)
    P1/2, N=201, Terminated, Incyte Corporation | Completed --> Terminated
    Trial termination • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine • docetaxel • Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr)
    almost3years
    Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Peter Hosein, MD | Trial completion date: Apr 2026 --> Sep 2027 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR
    |
    Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)
    almost3years
    SAFETY, TOLERABILITY, AND EFFICACY OF TAR-200 IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO REFUSED OR WERE UNFIT FOR CURATIVE-INTENT THERAPY: A PHASE 1 STUDY (WSAUA 2022)
    TAR-200 was generally safe, well tolerated, and demonstrated preliminary efficacy in this elderly and frail cohort with limited treatment options. TAR-200 is currently under investigation in combination with the systemic inhibitor of programmed cell death protein-1 cetrelimab in the SunRISe clinical trials program (NCT04640623, NCT04658862, NCT04919512).
    Clinical • P1 data
    |
    PD-1 (Programmed cell death 1)
    |
    cetrelimab (JNJ-63723283) • Inlexzo (gemcitabine intravesical system)